Author

Maurizio Scaltriti

AstraZeneca (United Kingdom)ORCID 0000-0002-5522-1447Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Maurizio Scaltriti1 paper

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:database / resource· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:snRNA-seq· 1 Research Focus:software / tool· 1

Frequent Co-Authors

Anton Mikhailovich SafonoviD· 1 shared Antonio MarraiD· 1 shared Asaf RotemiD· 1 shared Ben O’LearyiD· 1 shared Bob T. LiiD· 1 shared Bradley Stephen WubbenhorstiD· 1 shared Brian Andrew DoughertyiD· 1 shared Chaitanya BandlamudiiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Anton Mikhailovich SafonovORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GenomicsCell Reports MethodsPeer-reviewedMar 1, 2026

Comprehensive cellular analysis with single-nucleus RNA-seq of archived PAXgene whole blood samples

Ojasvi Chaudhary, Mia K. Steinberg, Grant E. Duclos…·Asaf Rotem

The paper develops a method for single-nucleus RNA-seq of archived PAXgene whole blood samples, achieving high nuclei yields and unbiased cell-type representation through optimized isolation and globin depletion.

1 citation

𝕏 PostBluesky

GenomicsbioRxivPreprintFeb 5, 2024

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi…·Pedram Razavi

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.

18 citations

humanwhole-exome sequencing

𝕏 PostBluesky